Lloyd-Evans E, Platt FM. Lipids on trial: the search for the offending metabolite in Niemann-pick type C disease. Traffic. 2010;11(4):419–28.

Article  CAS  PubMed  Google Scholar 

Vanier MT. Niemann-pick disease type C. Orphanet J Rare Dis. 2010;5:16.

Article  PubMed  PubMed Central  Google Scholar 

Stampfer M, Theiss S, Amraoui Y, Jiang X, Keller S, Ory DS, Mengel E, Fischer C, Runz H. Niemann-pick disease type C clinical database: cognitive and coordination deficits are early disease indicators. Orphanet J Rare Dis. 2013;8:35.

Article  PubMed  PubMed Central  Google Scholar 

Wraith JE, Sedel F, Pineda M, Wijburg FA, Hendriksz CJ, Fahey M, Walterfang M, Patterson MC, Chadha-Boreham H, Kolb SA. Niemann-pick type C suspicion index tool: analyses by age and association of manifestations. J Inherit Metab Dis. 2014;37(1):93–101.

Article  CAS  PubMed  Google Scholar 

Geberhiwot T, Moro A, Dardis A, Ramaswami U, Sirrs S, Marfa MP, Vanier MT, Walterfang M, Bolton S, Dawson C, et al. Consensus clinical management guidelines for Niemann-pick disease type C. Orphanet J Rare Dis. 2018;13(1):50.

Article  PubMed  PubMed Central  Google Scholar 

Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F, Group N-CGW. Recommendations for the diagnosis and management of Niemann-pick disease type C: an update. Mol Genet Metab. 2012;106(3):330–44.

Article  CAS  PubMed  Google Scholar 

Dardis A, Zampieri S, Gellera C, Carrozzo R, Cattarossi S, Peruzzo P, Dariol R, Sechi A, Deodato F, Caccia C et al. Molecular Genetics of Niemann-pick type C disease in Italy: an update on 105 patients and description of 18 NPC1 novel variants. J Clin Med 2020, 9(3).

Park WD, O’Brien JF, Lundquist PA, Kraft DL, Vockley CW, Karnes PS, Patterson MC, Snow K. Identification of 58 novel mutations in Niemann-pick disease type C: correlation with biochemical phenotype and importance of PTC1-like domains in NPC1. Hum Mutat. 2003;22(4):313–25.

Article  CAS  PubMed  Google Scholar 

Higgins ME, Davies JP, Chen FW, Ioannou YA. Niemann-pick C1 is a late endosome-resident protein that transiently associates with lysosomes and the trans-golgi network. Mol Genet Metab. 1999;68(1):1–13.

Article  CAS  PubMed  Google Scholar 

Xu Y, Zhang Q, Tan L, Xie X, Zhao Y. The characteristics and biological significance of NPC2: mutation and disease. Mutat Res Rev Mutat Res. 2019;782:108284.

Article  CAS  PubMed  Google Scholar 

Sleat DE, Wiseman JA, El-Banna M, Price SM, Verot L, Shen MM, Tint GS, Vanier MT, Walkley SU, Lobel P. Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport. Proc Natl Acad Sci U S A. 2004;101(16):5886–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Solomon BI, Smith AC, Sinaii N, Farhat N, King MC, Machielse L, Porter FD. Association of Miglustat with swallowing outcomes in Niemann-pick Disease, Type C1. JAMA Neurol. 2020;77(12):1564–8.

Article  PubMed  Google Scholar 

Grogan K. FDA rejects Actelion’s Zavesca for rare NP-C disease. In.: PharmaTimes Online; 2010.

Actelion Pharmaceuticals Ltd (CH). - Actelion receives FDA complete response letter for Zavesca (miglustat) for the treatment of Niemann-Pick type C disease. https://www.drugs.com/nda/actelion-pharmaceuticals-ltd-ch-actelion-receives-fda-complete-response-letter-zavesca-miglustat-2828.html.

Bremova-Ertl T, Claassen J, Foltan T, Gascon-Bayarri J, Gissen P, Hahn A, Hassan A, Hennig A, Jones SA, Kolnikova M, et al. Efficacy and safety of N-acetyl-L-leucine in Niemann-pick disease type C. J Neurol. 2022;269(3):1651–62.

Article  CAS  PubMed  Google Scholar 

Mengel E, Patterson MC, Da Riol RM, Del Toro M, Deodato F, Gautschi M, Grunewald S, Gronborg S, Harmatz P, Heron B, et al. Efficacy and safety of arimoclomol in Niemann-pick disease type C: results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment. J Inherit Metab Dis. 2021;44(6):1463–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bremova-Ertl T, Ramaswami U, Brands M, Foltan T, Gautschi M, Gissen P, Gowing F, Hahn A, Jones S, Kay R, et al. Trial of N-Acetyl-l-Leucine in Niemann-pick Disease Type C. N Engl J Med. 2024;390(5):421–31.

Article  PubMed  Google Scholar 

Sharma R, Hastings C, Staretz-Chacham O, Raiman J, Paucar M, Spiegel R, Murray B, Hurst B, Liu B, Kjems L, et al. Long-term administration of intravenous trappsol(R) Cyclo (HP-beta-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-pick disease type C1: results of an international 48-week phase I/II trial. Mol Genet Metab Rep. 2023;36:100988.

CAS  PubMed  PubMed Central  Google Scholar 

Ory DS, Ottinger EA, Farhat NY, King KA, Jiang X, Weissfeld L, Berry-Kravis E, Davidson CD, Bianconi S, Keener LA, et al. Intrathecal 2-hydroxypropyl-beta-cyclodextrin decreases neurological disease progression in Niemann-pick disease, type C1: a non-randomised, open-label, phase 1–2 trial. Lancet. 2017;390(10104):1758–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cagney DN, Sul J, Huang RY, Ligon KL, Wen PY, Alexander BM. The FDA NIH Biomarkers, EndpointS, and other tools (BEST) resource in neuro-oncology. Neuro Oncol. 2018;20(9):1162–72.

Article  CAS  PubMed  Google Scholar 

Walkley SU, Suzuki K. Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim Biophys Acta. 2004;1685(1–3):48–62.

Article  CAS  PubMed  Google Scholar 

Vig PJ, Subramony SH, Burright EN, Fratkin JD, McDaniel DO, Desaiah D, Qin Z. Reduced immunoreactivity to calcium-binding proteins in Purkinje cells precedes onset of ataxia in spinocerebellar ataxia-1 transgenic mice. Neurology. 1998;50(1):106–13.

Article  CAS  PubMed  Google Scholar 

Barski JJ, Hartmann J, Rose CR, Hoebeek F, Morl K, Noll-Hussong M, De Zeeuw CI, Konnerth A, Meyer M. Calbindin in cerebellar Purkinje cells is a critical determinant of the precision of motor coordination. J Neurosci. 2003;23(8):3469–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ko DC, Milenkovic L, Beier SM, Manuel H, Buchanan J, Scott MP. Cell-autonomous death of cerebellar purkinje neurons with autophagy in Niemann-pick type C disease. PLoS Genet. 2005;1(1):81–95.

Article  CAS  PubMed  Google Scholar 

Vite CH, Bagel JH, Swain GP, Prociuk M, Sikora TU, Stein VM, O’Donnell P, Ruane T, Ward S, Crooks A, et al. Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-pick type C1 disease. Sci Transl Med. 2015;7(276):276ra226.

Article  Google Scholar 

Kiyosawa K, Mokuno K, Murakami N, Yasuda T, Kume A, Hashizume Y, Takahashi A, Kato K. Cerebrospinal fluid 28-kDa calbindin-D as a possible marker for Purkinje cell damage. J Neurol Sci. 1993;118(1):29–33.

Article  CAS  PubMed  Google Scholar 

Campbell K, Cawley NX, Luke R, Scott KEJ, Johnson N, Farhat NY, Alexander D, Wassif CA, Li W, Cologna SM, et al. Identification of cerebral spinal fluid protein biomarkers in Niemann-pick disease, type C1. Biomark Res. 2023;11(1):14.

Article  PubMed  PubMed Central  Google Scholar 

Baimbridge KG, Miller JJ, Parkes CO. Calcium-binding protein distribution in the rat brain. Brain Res. 1982;239(2):519–25.

Article  CAS  PubMed  Google Scholar 

Bradbury A, Bagel J, Sampson M, Farhat N, Ding W, Swain G, Prociuk M, O’Donnell P, Drobatz K, Gurda B, et al. Cerebrospinal fluid calbindin D concentration as a Biomarker of Cerebellar Disease Progression in Niemann-pick type C1 disease. J Pharmacol Exp Ther. 2016;358(2):254–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Disanto G, Barro C, Benkert P, Naegelin Y, Schadelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuhle J, Plattner K, Bestwick JP, Lindberg RL, Ramagopalan SV, Norgren N, Nissim A, Malaspina A, Leppert D, Giovannoni G, et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler. 2013;19(12):1597–603.

Article